1
Participants
Start Date
February 11, 2022
Primary Completion Date
August 5, 2022
Study Completion Date
August 5, 2022
AK120
AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
AK120
AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
AK120
AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
Placebo
Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
The Second Hospital of Anhui Medical University, Hefei
Beijing Jingmei General Hospital, Beijing
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
Cangzhou People's Hospital, Cangzhou
The Second Hospital of Hebei Medical University, Shijiazhuang
Luoyang Central Hospital, Luoyang
Henan Provincial People's Hospital, Zhengzhou
Baogang Hospital, Inner Mongolia, China, Baotou
Inner Mongolia People's Hospital, Hohhot
Zhongda Hospital Southeast University, Nanjing
Jiangxi Provincial Prople's Hospita, Nanchang
Jiangxi Pingxiang People's Hospital, Pingxiang
Jilin Province People's Hospital, Changchun
Shanghai General Hospital, Shanghai
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
Zhongshan Hospital Fudan University, Shanghai
First Hospital of Shanxi Medical University, Taiyuan
The Second Affiliated Hospital Zhejiang University School of Medicine,, Hangzhou
Lead Sponsor
Akeso
INDUSTRY